|
1
|
World Health Organization: Global Health
Observatory data repository 2011. Number of deaths (world) by
cause; http://apps.who.int/gho/data/node.main.CODWORLD?lang=enAccessed.
October 31–2013
|
|
2
|
American Cancer Society: Cancer Facts
& Figures 2015. US Mortality Data, National Center for Health
Statistic Center for Disease, Control & Prevention.
2015.https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2015.html
|
|
3
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin MD, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bies C, Lehr CM and Woodley JF:
Lectin-mediated drug targeting: History and applications. Adv Drug
Deliv Rev. 56:425–435. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu LG, Fernig DG, White MR, Spiller DG,
Appleton P, Evans RC, Grierson I, Smith JA, Davies H, Gerasimenko
OV, et al: Edible mushroom (Agaricus bisporus) lectin, which
reversibly inhibits epithelial cell proliferation, blocks nuclear
localization sequence-dependent nuclear protein import. J Biol
Chem. 274:4890–4899. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu L, Fernig DG, Smith JA, Milton JD and
Rhodes JM: Reversible inhibition of proliferation of epithelial
cell lines by Agaricus bisporus (edible mushroom) lectin.
Cancer Res. 53:4627–4632. 1993.PubMed/NCBI
|
|
7
|
Zhao C, Sun H, Tong X and Qi Y: An
antitumour lectin from the edible mushroom Agrocybe
aegerita. Biochem J. 374:321–327. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang S, Chen Y, Wang M, Yin Y, Pan Y, Gu
B, Yu G, Li Y, Wong BH, Liang Y, et al: A novel lectin from
Agrocybe aegerita shows high binding selectivity for
terminal N-acetylglucosamine. Biochem J. 443:369–378. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang HX, Liu WK, Ng TB, Ooi VE and Chang
ST: The immunomodulatory and antitumor activities of lectins from
the mushroom Tricholoma mongolicum. Immunopharmacology.
31:205–211. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li YR, Liu QH, Wang HX and Ng TB: A novel
lectin with potent antitumor, mitogenic and HIV-1 reverse
transcriptase inhibitory activities from the edible mushroom
Pleurotus citrinopileatus. Biochim Biophys Acta. 1780:51–57.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang GQ, Sun J, Wang HX and Ng TB: A
novel lectin with antiproliferative activity from the medicinal
mushroom Pholiota adiposa. Acta Biochim Pol. 56:415–421.
2009.PubMed/NCBI
|
|
12
|
Swamy BM, Hegde GV, Naik RS and Inamdar
SR: T-antigen binding lectin from the phytopathogenic fungus
Sclerotium rolfsii. Lect. Biol Biochem Clin Biochem.
15:45–55. 2001.
|
|
13
|
Chachadi VB, Inamdar SR, Yu LG, Rhodes JM
and Swamy BM: Exquisite binding specificity of Sclerotium
rolfsii lectin toward TF-related O-linked mucin-type glycans.
Glycoconj J. 28:49–56. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu LG: The oncofetal Thomsen-Friedenreich
carbohydrate antigen in cancer progression. Glycoconj J.
24:411–420. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Leonidas DD, Swamy BM, Hatzopoulos GN,
Gonchigar SJ, Chachadi VB, Inamdar SR, Zographos SE and Oikonomakos
NG: Structural basis for the carbohydrate recognition of the
Sclerotium rolfsii lectin. J Mol Biol. 368:1145–1161. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Inamdar SR, Savanur MA, Eligar SM,
Chachadi VB, Nagre NN, Chen C, Barclays M, Ingle A, Mahajan P,
Borges A, et al: The TF-antigen binding lectin from Sclerotium
rolfsii inhibits growth of human colon cancer cells by inducing
apoptosis in vitro and suppresses tumor growth in vivo.
Glycobiology. 22:1227–1235. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Savanur MA, Eligar SM, Pujari R, Chen C,
Mahajan P, Borges A, Shastry P, Ingle A, Kalraiya RD, Swamy BM, et
al: Sclerotium rolfsii lectin induces stronger inhibition of
proliferation in human breast cancer cells than normal human
mammary epithelial cells by induction of cell apoptosis. PLoS One.
9:e1101072014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eligar SM, Pujari R, Swamy BM, Shastry P
and Inamdar SR: Sclerotium rolfsii lectin inhibits
proliferation and induces apoptosis in human ovarian cancer cell
line PA-1. Cell Prolif. 45:397–403. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Barkeer S, Guha N, Hothpet V, Adavigowda
Saligrama D, Hegde P, Padmanaban A, Yu LG, Swamy BM and Inamdar SR:
Molecular mechanism of anticancer effect of Sclerotium
rolfsii lectin in HT29 cells involves differential expression
of genes associated with multiple signaling pathways: A microarray
analysis. Glycobiology. 25:1375–1391. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Barkeer S, Gudihal R, Eligar SM, Hegde P,
Lu GY, Bale MS and Inamdar SR: Identification and characterization
of Sclerotium rolfsii lectin (SRL) binding proteins from
human colon epithelial cancer HT29 cells. Translational Biomedicine
ISSN 2172-0479. 2015.
|
|
21
|
Sharma SK, Pedley RB, Bhatia J, Boxer GM,
El-Emir E, Qureshi U, Tolner B, Lowe H, Michael NP, Minton N, et
al: Sustained tumor regression of human colorectal cancer
xenografts using a multifunctional mannosylated fusion protein in
antibody-directed enzyme prodrug therapy. Clin Cancer Res.
11:814–825. 2005.PubMed/NCBI
|
|
22
|
Vallespí MG, Pimentel G, Cabrales-Rico A,
Garza J, Oliva B, Mendoza O, Gomez Y, Basaco T, Sánchez I, Calderón
C, et al: Antitumor efficacy, pharmacokinetic and biodistribution
studies of the anticancer peptide CIGB-552 in mouse models. J Pept
Sci. 20:850–859. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ingle AD and Hosetti BB: Use of
immuno-compromised mouse model for establishment and study of human
animal tumours. Indian J Vet Pathol. 34:156–161. 2010.
|
|
24
|
Simpson RJ: Homogenization of mammalian
tissue. Cold Spring Harb Protoc pdb prot 5455. 2010.https://doi.org/10.1101/pdb.prot5455https://doi.org/10.1101/pdb.prot5455.
View Article : Google Scholar
|
|
25
|
Burden DW: Guide to the Homogenization of
Biological Samples. Random Primers. 7:2008.1–14, 2008. http://www.opsdiagnostics.com/notes/ranpri/Homogenization%20Guide%20ver.pdf
|
|
26
|
Hartmann C, Smeyers-Verbeke J, Massart DL
and McDowall RD: Validation of bioanalytical chromatographic
methods. J Pharm Biomed Anal. 17:193–218. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ahn JE, Karlsson MO, Dunne A and Ludden
TM: Likelihood based approaches to handling data below the
quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn.
35:401–421. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jusko WJ: Use of pharmacokinetic data
below lower limit of quantitation values. Pharm Res. 29:2628–2631.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Beal SL: Ways to fit a PK model with some
data below the quantification limit. J Pharmacokinet Pharmacodyn.
28:481–504. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sallam H, El-Serafi I, Meijer L and Hassan
M: Pharmacokinetics and biodistribution of the cyclin-dependent
kinase inhibitor -CR8- in mice. BMC Pharmacol Toxicol. 14:502013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Khlebtsov N and Dykman L: Biodistribution
and toxicity of engineered gold nanoparticles: A review of in vitro
and in vivo studies. Chem Soc Rev. 40:1647–1671. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ghazarian H, Idoni B and Oppenheimer SB: A
glycobiology review: Carbohydrates, lectins and implications in
cancer therapeutics. Acta Histochem. 113:236–247. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Campbell BJ, Finnie IA, Hounsell EF and
Rhodes JM: Direct demonstration of increased expression of
Thomsen-Friedenreich (TF) antigen in colonic adenocarcinoma and
ulcerative colitis mucin and its concealment in normal mucin. J
Clin Invest. 95:571–576. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Singh R, Campbell BJ, Yu LG, Fernig DG,
Milton JD, Goodlad RA, FitzGerald AJ and Rhodes JM: Cell
surface-expressed Thomsen-Friedenreich antigen in colon cancer is
predominantly carried on high molecular weight splice variants of
CD44. Glycobiology. 11:587–592. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hanisch FG and Baldus SE: The
Thomsen-Friedenreich (TF) antigen: A critical review on the
structural, biosynthetic and histochemical aspects of a
pancarcinoma-associated antigen. Histol Histopathol. 12:263–281.
1997.PubMed/NCBI
|
|
36
|
Almogren A, Abdullah J, Ghapure K,
Ferguson K, Glinsky VV and Rittenhouse-Olson K:
Anti-Thomsen-Friedenreich-Ag (anti-TF-Ag) potential for cancer
therapy. Front Biosci (Schol Ed). 4:840–863. 2012.PubMed/NCBI
|
|
37
|
Belov L, Zhou J and Christopherson RI:
Cell surface markers in colorectal cancer prognosis. Int J Mol Sci.
12:78–113. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Singh R, Subramanian S, Rhodes JM and
Campbell BJ: Peanut lectin stimulates proliferation of colon cancer
cells by interaction with glycosylated CD44v6 isoforms and
consequential activation of c-Met and MAPK: Functional implications
for disease-associated glycosylation changes. Glycobiology.
16:594–601. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yau T, Dan X, Ng CC and Ng TB: Lectins
with potential for anti-cancer therapy. Molecules. 20:3791–3810.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mitchell BS and Schumacher U: The use of
the lectin Helix pomatia agglutinin (HPA) as a prognostic
indicator and as a tool in cancer research. Histol Histopathol.
14:217–226. 1999.PubMed/NCBI
|
|
41
|
Peiris D, Ossondo M, Fry S, Loizidou M,
Smith-Ravin J and Dwek MV: Identification of O-linked
glycoproteins binding to the lectin Helix pomatia agglutinin
as markers of metastatic colorectal cancer. PLoS One.
10:e01383452015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu B, Wu JM, Li J, Liu JJ, Li WW, Li CY,
Xu HL and Bao JK: Polygonatum cyrtonema lectin induces
murine fibrosarcoma L929 cell apoptosis and autophagy via blocking
Ras-Raf and PI3K-Akt signaling pathways. Biochimie. 92:1934–1938.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang SY, Yu QJ, Bao JK and Liu B:
Polygonatum cyrtonema lectin, a potential antineoplastic
drug targeting programmed cell death pathways. Biochem Biophys Res
Commun. 406:497–500. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kang TB, Song SK, Yoon TJ, Yoo YC, Lee KH,
Her E and Kim JB: Isolation and characterization of two Korean
mistletoe lectins. J Biochem Mol Biol. 40:959–965. 2007.PubMed/NCBI
|
|
45
|
Yoon TJ, Yoo YC, Kang TB, Song SK, Lee KB,
Her E, Song KS and Kim JB: Antitumor activity of the Korean
mistletoe lectin is attributed to activation of macrophages and NK
cells. Arch Pharm Res. 26:861–867. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rostock M, Huber R, Greiner T, Fritz P,
Scheer R, Schueler J and Fiebig HH: Anticancer activity of a
lectin-rich mistletoe extract injected intratumorally into human
pancreatic cancer xenografts. Anticancer Res. 25:1969–1975.
2005.PubMed/NCBI
|
|
47
|
Miyagi T, Takehara T, Tatsumi T, Suzuki T,
Jinushi M, Kanazawa Y, Hiramatsu N, Kanto T, Tsuji S, Hori M, et
al: Concanavalin a injection activates intrahepatic innate immune
cells to provoke an antitumor effect in murine liver. Hepatology.
40:1190–1196. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lei HY and Chang CP: Lectin of
Concanavalin A as an anti-hepatoma therapeutic agent. J Biomed Sci.
16:102009. View Article : Google Scholar : PubMed/NCBI
|
